Preclinical studies demonstrate that NSC768313 disrupts cancer cell proliferation by targeting PI-PLC isoforms, particularly PI-PLCδ, thereby suppressing the hydrolysis of PI(4,5)P2 into DAG and inositol trisphosphate IP3. Here, PLCB1 is linked to cancer.